Compare AQMS & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQMS | LEXX |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 8.7M |
| IPO Year | 2015 | 2011 |
| Metric | AQMS | LEXX |
|---|---|---|
| Price | $2.69 | $10.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $1.50 |
| AVG Volume (30 Days) | 27.2K | ★ 96.8K |
| Earning Date | 05-05-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,100,000.00 | $705,923.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $600.00 | $601.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $2.46 | $0.35 |
| 52 Week High | $39.37 | $9.18 |
| Indicator | AQMS | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 94.42 |
| Support Level | $2.49 | $0.65 |
| Resistance Level | $2.98 | N/A |
| Average True Range (ATR) | 0.19 | 0.76 |
| MACD | 0.04 | 0.62 |
| Stochastic Oscillator | 63.45 | 96.42 |
Aqua Metals Inc is developing and seeking to commercialize proprietary recycling and refining technologies for the recovery of critical minerals and metals. Its patented and patent-pending AquaRefining process is an electro-hydrometallurgical method designed to recover high-purity materials from battery and other metal-bearing feedstocks using a closed-loop system powered by electricity. Its idea is to reduce CAPEX and OPEX costs, reduce emissions, hazardous waste, and reliance on conventional smelting and chemical-intensive refining processes. It has one operating segment: sustainable metals recycling. It focused on the development and commercialization of AquaRefining technology for the clean and efficient recovery of valuable metals from lead-acid and lithium-ion batteries.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.